Literature DB >> 16684811

Role of risperidone in children with autism spectrum disorder.

Benjamin Chavez1, Mapy Chavez-Brown, Jose A Rey.   

Abstract

OBJECTIVE: To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD). DATA SOURCES: Searches of MEDLINE/PubMed (1992-February 2006) were conducted, as well as an extensive manual review of journals, using the key words autism and risperidone. STUDY SELECTION AND DATA EXTRACTION: Only double-blind, placebo-controlled trials were included for review. DATA SYNTHESIS: ASD is the most common of the pervasive developmental disorders. The main characteristics (core symptoms) of autism are impairment in social skills, problems communicating, and stereotypical movements. Behavioral manifestations or maladaptive behaviors include aggression, irritability, hyperactivity, inattention, impulsivity, tantrums, and self-injurious behavior.
CONCLUSIONS: Based on the data examined, risperidone appears efficacious and safe for treating certain behavioral aspects of autism including irritability, aggression, hyperactivity, and stereotypy. It does not appear to be as effective for the treatment of the core symptoms of autism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684811     DOI: 10.1345/aph.1G389

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Targeting the glutamate system in the treatment of autistic spectrum disorders.

Authors:  Joseph F Cubells
Journal:  Curr Psychiatry Rep       Date:  2007-04       Impact factor: 5.285

Review 2.  Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.

Authors:  Tatiana M Kazdoba; Prescott T Leach; Mu Yang; Jill L Silverman; Marjorie Solomon; Jacqueline N Crawley
Journal:  Curr Top Behav Neurosci       Date:  2016

3.  Incidence of gastrointestinal symptoms in children with autism: a population-based study.

Authors:  Samar H Ibrahim; Robert G Voigt; Slavica K Katusic; Amy L Weaver; William J Barbaresi
Journal:  Pediatrics       Date:  2009-07-27       Impact factor: 7.124

Review 4.  Atypical antipsychotics in children with pervasive developmental disorders.

Authors:  Benjamin Chavez; Mapy Chavez-Brown; Michael A Sopko; Jose A Rey
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.

Authors:  Gabriele Masi; Angela Cosenza; Stefania Millepiedi; Filippo Muratori; Cinzia Pari; Francesco Salvadori
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

Authors:  Jill L Silverman; Seda S Tolu; Charlotte L Barkan; Jacqueline N Crawley
Journal:  Neuropsychopharmacology       Date:  2009-12-23       Impact factor: 7.853

7.  Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents.

Authors:  Roberto Canitano; Valeria Scandurra
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

8.  Dysfunctional dopaminergic neurotransmission in asocial BTBR mice.

Authors:  M Squillace; L Dodero; M Federici; S Migliarini; F Errico; F Napolitano; P Krashia; A Di Maio; A Galbusera; A Bifone; M L Scattoni; M Pasqualetti; N B Mercuri; A Usiello; A Gozzi
Journal:  Transl Psychiatry       Date:  2014-08-19       Impact factor: 6.222

9.  Effectiveness and Adverse Effects of Risperidone in Children with Autism Spectrum Disorder in a Naturalistic Clinical Setting at a University Hospital in Oman.

Authors:  Salim Al-Huseini; Ali Al-Barhoumi; Miad Al-Balushi; Amira Al-Hosni; Tamadhir Al-Mahrouqi; Balqees Al-Mahrizi; Sanjay Jaju; Hassan Mirza
Journal:  Autism Res Treat       Date:  2022-01-31

Review 10.  Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.

Authors:  Christian Popow; Susanne Ohmann; Paul Plener
Journal:  Neuropsychiatr       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.